Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study.

In this study, use of the DB enabled assessments of the trends in drug use and AE incidence; we observed an increasing trend in the number of eribulin administrations and a decreasing trend in the use of concomitant hormone therapy with eribulin and AEs, such as anemia and pyrexia, over 5 or 6 years.

also in 47,180 other papers